4.7 Article

Development of an injectable alginate-collagen hydrogel for cardiac delivery of extracellular vesicles

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 629, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2022.122356

Keywords

Extracellular vesicles; Hydrogel; Myocardial infarction; Alginate; Collagen

Funding

  1. Spanish Ministry of Economy and Competitiveness [RYC2018-025897-I]
  2. University of Malaga
  3. Ministry of Science and innovation-State Research Agency
  4. FSE/Ministry of Science and innovation-State Research Agency
  5. [SAF2017-83734-R]
  6. [PID2020-119430RJ-I00]

Ask authors/readers for more resources

In this study, a novel injectable hydrogel (HG) based on alginate and collagen was developed as a delivery vehicle for extracellular vesicles (EVs) in cardiac repair. The HG exhibited good injectability, internal gel structure, and low viscosity, allowing for long-term retention in the heart and sustained release of EVs.
Extracellular vesicles (EVs) are nanosized particles with attractive therapeutic potential for cardiac repair. However, low retention and stability after systemic administration limit their clinical translation. As an alternative, the combination of EVs with biomaterial-based hydrogels (HGs) is being investigated to increase their exposure in the myocardium and achieve an optimal therapeutic effect. In this study, we developed and characterized a novel injectable in-situ forming HG based on alginate and collagen as a cardiac delivery vehicle for EVs. Different concentrations of alginate and collagen crosslinked with calcium gluconate were tested. Based on injectability studies, 1% alginate, 0.5 mg/mL collagen and 0.25% calcium gluconate HG was selected as the idoneous combination for cardiac administration using catheter-based systems. Rheological examination revealed that the HG possessed an internal gel structure, weak mechanical properties and low viscosity, facilitating an easy administration. In addition, EVs were successfully incorporated and homogeneously distributed in the HG. After administration in a rat model of myocardial infarction, the HG showed long-term retention in the heart and allowed for a sustained release of EVs for at least 7 days. Thus, the combination of HGs and EVs represents a promising therapeutic strategy for myocardial repair. Besides EVs delivery, the developed HG could represent a useful platform for cardiac delivery of multiple therapeutic agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available